Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly |
Autore | Kelly John <1961-> |
Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
Descrizione fisica | 1 online resource (326 p.) |
Disciplina | 615/.78 |
Soggetto topico |
Neuropharmacology
Drug development |
ISBN |
1-282-36283-6
9786612362835 0-470-68292-2 0-470-68291-4 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Principles of CNS drug development; Contents; Acknowledgements; Preface; Abbreviations; 1 Introduction; 1.1 The global burden of CNS disease; 1.2 Assessment of the global burden of disease; 1.3 The prevalence of CNS disorders; 1.4 Disability due to CNS disorders; 1.5 Economic Costs; 1.6 Concluding comments; References; 2 An overview of the major CNS disorders; 2.1 Introduction; 2.2 Overview of psychiatric disorders; 2.3 Overview of neurological/neurodegenerative disorders; 2.4 Concluding comments; References; 3 Neurobiological substrates of CNS disorders; 3.1 Introduction
3.2 Brief introduction to the principles of chemical neurotransmission3.3 Stages of chemical neurotransmission; 3.4 Approaches to investigating CNS alterations in CNS disorders; 3.5 Evidence for a neurobiological rationale for CNS disorders; 3.6 Concluding comments; References; 4 Current pharmacological targets; 4.1 Introduction; 4.2 Pharmacological treatments for depression; 4.3 Pharmacological treatments for schizophrenia; 4.4 Pharmacological treatments for anxiety disorders; 4.5 Pharmacological treatments for epilepsy; 4.6 Pharmacological treatments for Parkinson's disease 4.7 Pharmacological treatments for Alzheimer's disease4.8 Concluding comments; References; 5 Premarketing efficacy evaluation; 5.1 Introduction; 5.2 Target identification; 5.3 Lead optimisation; 5.4 Target validation in animal models; 5.5 The use of genetically modified animals in CNS drug development; 5.6 A selection of animal models of psychiatric disease; 5.7 A selection of animal models of neurodegenerative disease; 5.8 Which models to choose; 5.9 Clinical trials that evaluate drug efficacy; 5.10 Specific drug profiles; References 6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination6.1 Introduction; 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug?; 6.3 Absorption; 6.4 Distribution; 6.5 Metabolism; 6.6 Elimination; 6.7 Measurement of drug concentrations; 6.8 Factors that affect pharmacokinetics; 6.9 Allometric scaling; 6.10 Microdosing (Phase 0) Studies; 6.11 Dose prediction and therapeutic drug monitoring; 6.12 Stereoselectivity of metabolism of drugs; 6.13 Specific drug profiles; 6.14 Concluding comments; References; 7 Safety concerns; 7.1 Introduction 7.2 Postmarketing surveillance7.3 Acute poisoning; 7.4 Quantification of the relative risk of fatalities from CNS drugs; 7.5 Adverse drug reactions (ADRs); 7.6 Specific types of toxicity encountered with psychotropic drugs; 7.7 Safety concerns following long-term administration of CNS Drugs; 7.8 Polypharmacy; 7.9 Specific drug profiles; 7.10 Concluding comments; References; Websites; 8 Preclinical and clinical safety evaluation; 8.1 Introduction; 8.2 Preclinical exploratory toxicology and safety pharmacology evaluations; 8.3 Primary and secondary pharmacology; 8.4 Safety pharmacology 8.5 Toxicology studies required for regulatory purposes |
Record Nr. | UNINA-9910139897403321 |
Kelly John <1961->
![]() |
||
Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Principles of CNS drug development : from test tube to patient / / John Kelly |
Autore | Kelly John <1961-> |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
Descrizione fisica | 1 online resource (326 p.) |
Disciplina | 615/.78 |
Soggetto topico |
Neuropharmacology
Drug development |
ISBN |
1-282-36283-6
9786612362835 0-470-68292-2 0-470-68291-4 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Principles of CNS drug development; Contents; Acknowledgements; Preface; Abbreviations; 1 Introduction; 1.1 The global burden of CNS disease; 1.2 Assessment of the global burden of disease; 1.3 The prevalence of CNS disorders; 1.4 Disability due to CNS disorders; 1.5 Economic Costs; 1.6 Concluding comments; References; 2 An overview of the major CNS disorders; 2.1 Introduction; 2.2 Overview of psychiatric disorders; 2.3 Overview of neurological/neurodegenerative disorders; 2.4 Concluding comments; References; 3 Neurobiological substrates of CNS disorders; 3.1 Introduction
3.2 Brief introduction to the principles of chemical neurotransmission3.3 Stages of chemical neurotransmission; 3.4 Approaches to investigating CNS alterations in CNS disorders; 3.5 Evidence for a neurobiological rationale for CNS disorders; 3.6 Concluding comments; References; 4 Current pharmacological targets; 4.1 Introduction; 4.2 Pharmacological treatments for depression; 4.3 Pharmacological treatments for schizophrenia; 4.4 Pharmacological treatments for anxiety disorders; 4.5 Pharmacological treatments for epilepsy; 4.6 Pharmacological treatments for Parkinson's disease 4.7 Pharmacological treatments for Alzheimer's disease4.8 Concluding comments; References; 5 Premarketing efficacy evaluation; 5.1 Introduction; 5.2 Target identification; 5.3 Lead optimisation; 5.4 Target validation in animal models; 5.5 The use of genetically modified animals in CNS drug development; 5.6 A selection of animal models of psychiatric disease; 5.7 A selection of animal models of neurodegenerative disease; 5.8 Which models to choose; 5.9 Clinical trials that evaluate drug efficacy; 5.10 Specific drug profiles; References 6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination6.1 Introduction; 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug?; 6.3 Absorption; 6.4 Distribution; 6.5 Metabolism; 6.6 Elimination; 6.7 Measurement of drug concentrations; 6.8 Factors that affect pharmacokinetics; 6.9 Allometric scaling; 6.10 Microdosing (Phase 0) Studies; 6.11 Dose prediction and therapeutic drug monitoring; 6.12 Stereoselectivity of metabolism of drugs; 6.13 Specific drug profiles; 6.14 Concluding comments; References; 7 Safety concerns; 7.1 Introduction 7.2 Postmarketing surveillance7.3 Acute poisoning; 7.4 Quantification of the relative risk of fatalities from CNS drugs; 7.5 Adverse drug reactions (ADRs); 7.6 Specific types of toxicity encountered with psychotropic drugs; 7.7 Safety concerns following long-term administration of CNS Drugs; 7.8 Polypharmacy; 7.9 Specific drug profiles; 7.10 Concluding comments; References; Websites; 8 Preclinical and clinical safety evaluation; 8.1 Introduction; 8.2 Preclinical exploratory toxicology and safety pharmacology evaluations; 8.3 Primary and secondary pharmacology; 8.4 Safety pharmacology 8.5 Toxicology studies required for regulatory purposes |
Record Nr. | UNINA-9910817296903321 |
Kelly John <1961->
![]() |
||
Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|